Galectin-1 promotes tumor progression via NF-κB signaling pathway in epithelial ovarian cancer

Le Chen,Ying Yao,Lijuan Sun,Jie Tang

DOI: https://doi.org/10.7150/jca.20814

IF: 3.9

2017-01-01

Journal of Cancer

Abstract:<b>Purpose:</b> We previously reported that Galectin-1 (Gal-1) played a role in epithelial ovarian cancer (EOC) progression. In this study, we aimed to further investigate the association between Gal-1 expression and prognosis in EOC patients and tried to reveal some novel potential mechanisms of Gal-1 in EOC invasion and migration. <b>Materials and Methods:</b> Gal-1 and nucleus NF-κBp65 expression in 109 human epithelial ovarian cancer tissue specimens were evaluated by immunohistochemistry. The Cox model and survival curves were used to investigate the effect of Gal-1 on EOC prognosis. Correlation between Gal-1 expression and NF-κB activation in EOC patients was also analyzed. In vitro experiments were further performed to reveal the function and mechanisms of Gal-1 in invasion and migration of EOC cells. <b>Results:</b> Expression level of Gal-1 in EOC tissue was an independent prognostic factor on overall survival (<i>p&lt;</i>0.05) and progression-free survival (<i>p&lt;</i>0.05). Patients with high Galectin-1 expression had shorter overall survival (OS, <i>p&lt;</i>0.05)) and progression-free survival (PFS, <i>p&lt;</i>0.05). Immunohistochemistry revealed that expression of Gal-1 was positively associated with activation of NF-κBp65 in EOC tissues (Kappa coefficient=0.458, <i>p&lt;</i>0.001). Patients with tumors concomitantly co-over-expressing Gal-1 and NF-κBp65 had the worse OS (<i>p&lt;</i>0.001) and PFS (<i>p&lt;</i>0.001). The abilities of migration and invasion for EOC cells were significantly reduced after Gal-1 knocked-down in human EOC cell line HO8910, which was accompanied with the suppression of NF-κb pathway activation and with the matrix metalloproteinase-2 and matrix metalloproteinase-9 down-regulation. <b>Conclusions</b>: Our results suggest that Gal-1 is associated with poor outcome in EOC and Galectin-1 promotes tumor progression via NF-κB pathway activation in EOC.

oncology